Structures by: Maddileti D.
Total: 31
C23H33ClFN3O
C23H33ClFN3O
CrystEngComm (2012) 14, 7 2367
a=17.0708(14)Å b=11.9644(10)Å c=11.0576(9)Å
α=90.00° β=106.1890(10)° γ=90.00°
C23H31ClFN3
C23H31ClFN3
CrystEngComm (2012) 14, 7 2367
a=7.485(10)Å b=8.578(9)Å c=16.794(18)Å
α=82.718(17)° β=85.478(17)° γ=84.883(11)°
C24H18BiN3O9
C24H18BiN3O9
Dalton transactions (Cambridge, England : 2003) (2012) 41, 3 1004-1012
a=9.6708(10)Å b=11.4133(12)Å c=11.5410(12)Å
α=77.802(2)° β=78.026(3)° γ=72.353(2)°
C34H27BiN6O12
C34H27BiN6O12
Dalton transactions (Cambridge, England : 2003) (2012) 41, 3 1004-1012
a=9.9818(12)Å b=13.8686(16)Å c=13.9078(16)Å
α=73.185(2)° β=70.121(2)° γ=70.084(2)°
C21H17BiN6O7
C21H17BiN6O7
Dalton transactions (Cambridge, England : 2003) (2012) 41, 3 1004-1012
a=27.571(2)Å b=10.2872(8)Å c=17.0803(13)Å
α=90.00° β=109.0150(10)° γ=90.00°
C26H19BiN2O5
C26H19BiN2O5
Dalton transactions (Cambridge, England : 2003) (2012) 41, 3 1004-1012
a=10.120(2)Å b=13.740(3)Å c=16.630(3)Å
α=90.00° β=101.00(3)° γ=90.00°
C17H13BiO3
C17H13BiO3
Dalton transactions (Cambridge, England : 2003) (2012) 41, 3 1004-1012
a=10.340(2)Å b=9.7251(19)Å c=15.679(3)Å
α=90.00° β=101.02(3)° γ=90.00°
C16H11BiO4S2
C16H11BiO4S2
Dalton transactions (Cambridge, England : 2003) (2012) 41, 3 1004-1012
a=8.6447(8)Å b=9.6012(9)Å c=10.6965(10)Å
α=81.2790(10)° β=71.4180(10)° γ=71.4290(10)°
C51H39Bi3O6S3
C51H39Bi3O6S3
Dalton transactions (Cambridge, England : 2003) (2012) 41, 3 1004-1012
a=9.238(2)Å b=17.369(4)Å c=30.368(7)Å
α=90.00° β=90.00° γ=90.00°
Carglumic Acid
C6H10N2O5
CrystEngComm (2015) 17, 28 5252
a=5.1179(8)Å b=12.2079(18)Å c=12.7508(19)Å
α=90.00° β=90.00° γ=90.00°
Carglumic Acid
C6H10N2O5
CrystEngComm (2015) 17, 28 5252
a=5.3615(5)Å b=15.8123(15)Å c=9.9631(9)Å
α=90.00° β=90.899(2)° γ=90.00°
Febuxostat
C16H16N2O3S
Crystal Growth & Design (2013) 13, 7 3188
a=4.6756(4)Å b=17.6317(15)Å c=19.4992(15)Å
α=90.00° β=94.523(8)° γ=90.00°
Febuxostat-Nicotinamide
C16H16N2O3S,C6H6N2O
Crystal Growth & Design (2013) 13, 7 3188
a=6.9957(5)Å b=11.6356(11)Å c=13.7925(11)Å
α=102.644(7)° β=91.221(6)° γ=90.410(7)°
Febuxostat-PABA
C16H16N2O3S,C7H7NO2
Crystal Growth & Design (2013) 13, 7 3188
a=8.4227(9)Å b=11.1544(12)Å c=12.9327(14)Å
α=79.689(2)° β=81.524(2)° γ=68.220(2)°
Febuxostat-Acetamide
C16H16N2O3S,C2H5NO
Crystal Growth & Design (2013) 13, 7 3188
a=10.8516(4)Å b=23.6670(9)Å c=7.4362(4)Å
α=90.00° β=95.290(4)° γ=90.00°
Febuxostat-urea
C16H16N2O3S,CH4N2O
Crystal Growth & Design (2013) 13, 7 3188
a=7.6525(13)Å b=10.9684(18)Å c=12.261(2)Å
α=82.627(3)° β=71.822(3)° γ=69.866(3)°
Blonanserinium nicotinate salt
C23H31FN3,C6H4NO2
Crystal Growth & Design (2014) 14, 5 2557
a=12.2184(12)Å b=11.6715(9)Å c=18.5188(17)Å
α=90.00° β=94.867(8)° γ=90.00°
Blonanserinium mesylate monohydrate
C23H31FN3,CH3O3S,H2O
Crystal Growth & Design (2014) 14, 5 2557
a=6.7308(8)Å b=10.5808(13)Å c=34.376(4)Å
α=90.00° β=91.931(2)° γ=90.00°
Blonanserinium mesylate salt
C23H31FN3,CH3O3S
Crystal Growth & Design (2014) 14, 5 2557
a=12.6945(9)Å b=13.7444(9)Å c=14.4954(10)Å
α=98.5020(10)° β=98.8410(10)° γ=105.9490(10)°
Blonanserinium succinate salt
C23H31FN3,C4H5O4
Crystal Growth & Design (2014) 14, 5 2557
a=8.9999(9)Å b=13.0762(13)Å c=21.704(2)Å
α=90.00° β=90.00° γ=90.00°
Blonanserin-suberic acid cocrystal
C23H30FN3,0.5(C8H14O4)
Crystal Growth & Design (2014) 14, 5 2557
a=13.655(12)Å b=11.540(10)Å c=15.669(14)Å
α=90.00° β=103.515(13)° γ=90.00°
Blonanserinium tosylate salt
C23H31FN3,C7H7O3S
Crystal Growth & Design (2014) 14, 5 2557
a=6.3176(9)Å b=36.767(5)Å c=11.6580(17)Å
α=90.00° β=99.549(2)° γ=90.00°
Trimethoprim
C14H18N4O3
Crystal Growth & Design (2015) 15, 4 1745
a=7.9202(8)Å b=10.4378(11)Å c=10.5434(11)Å
α=106.8710(10)° β=101.686(2)° γ=111.8230(10)°
Trimethoprim
C14H18N4O3
Crystal Growth & Design (2015) 15, 4 1745
a=18.250(2)Å b=5.9580(7)Å c=12.7527(14)Å
α=90.00° β=93.969(2)° γ=90.00°
Isoniazid-Ferulic acid
C10H10O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=7.3931(8)Å b=7.5175(10)Å c=15.0471(16)Å
α=82.133(10)° β=77.444(9)° γ=73.205(10)°
Isoniazid-Vanillic acid
C8H8O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=7.3139(5)Å b=7.4461(6)Å c=14.2942(9)Å
α=101.678(6)° β=91.124(5)° γ=109.433(7)°
Isoniazid-Resorcinol
C6H7N3O,C6H6O2
Crystal Growth & Design (2014) 14, 11 5991
a=5.0623(5)Å b=16.119(2)Å c=14.6266(15)Å
α=90.00° β=96.618(10)° γ=90.00°
Isoniazid-Caffeic acid
C9H8O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=7.4051(16)Å b=9.733(2)Å c=10.384(2)Å
α=74.183(3)° β=84.064(4)° γ=78.944(3)°
Isoniazid-Vanillic acid
C8H8O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=25.379(3)Å b=4.9943(6)Å c=22.281(3)Å
α=90.00° β=91.741(12)° γ=90.00°
Hydantoin-5-propionic acid
C6H8N2O4
CrystEngComm (2015) 17, 28 5252
a=6.2475(4)Å b=7.1111(6)Å c=17.3692(11)Å
α=90.00° β=96.792(5)° γ=90.00°
Isoniazid-Caffeic acid
C9H8O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=7.2470(12)Å b=20.694(4)Å c=9.6836(16)Å
α=90.00° β=100.974(3)° γ=90.00°